Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Phase IIB clinical trial initiated for treating hepatitis B-associated liver cancer

Phase IIB clinical trial initiated for treating hepatitis B-associated liver cancer

New treatment improves survival for people with common liver cancer

New treatment improves survival for people with common liver cancer

A new combinatorial therapy for treatment of liver cancer

A new combinatorial therapy for treatment of liver cancer

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

Scientists discover potential drug compounds that target common type of liver cancer

Scientists discover potential drug compounds that target common type of liver cancer

Scientists modify approved cancer drug to develop new antibiotic

Scientists modify approved cancer drug to develop new antibiotic

Experimental drug better for repeat kidney cancer patients than FDA-approved equivalent

Experimental drug better for repeat kidney cancer patients than FDA-approved equivalent

Combination therapy improves survival in patients with hepatocellular carcinoma

Combination therapy improves survival in patients with hepatocellular carcinoma

Study confirms effectiveness of a combination therapy for advanced liver cancer

Study confirms effectiveness of a combination therapy for advanced liver cancer

Repurposing drugs to outsmart cancers

Repurposing drugs to outsmart cancers

Platinum nanoparticles show selective toxicity against liver cancer cells

Platinum nanoparticles show selective toxicity against liver cancer cells

Physicians more likely to prescribe drugs of manufacturers who paid them money

Physicians more likely to prescribe drugs of manufacturers who paid them money

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

New nanoplatform technology may reverse drug-resistance in renal cell carcinoma

New nanoplatform technology may reverse drug-resistance in renal cell carcinoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets